Alder BioPharmaceuticals Inc

Most Recent

  • uploads///sales estimates
    Company & Industry Overviews

    Competition Dynamics for Ajovy—Teva’s Migraine Drug

    Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.

    By Sarah Collins
  • uploads///specialty products pipeline
    Company & Industry Overviews

    What’s the Latest on Teva’s Fremanezumab?

    Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches.

    By Sarah Collins
  • uploads///Lasmiditan
    Company & Industry Overviews

    What Will Help Eli Lilly Build a Stronger Migraine Portfolio?

    In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.

    By Daniel Collins
  • uploads///Part  Graph
    Company & Industry Overviews

    Biotechnology ETFs: Who Were the Top Performers Last Week?

    Biotechnology ETFs rose during the week ending April 1, 2016. The SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology ETF (IBB) rose 6.2% and 5.0%, respectively.

    By Peter Neil
  • uploads///Graph Part  Oct
    Company & Industry Overviews

    How are IBB’s Subgroups Performing?

    The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.